- Article metrics
- Last updated: Thu, 29 Jan 2026 18:01:16 Z
PI3K inhibitors are finally coming of age
Access & Citations
-
- 32k
- Article Accesses
-
- 420
- Citations
Citation counts are provided by Dimensions and depend on their data availability. Counts will update daily, once available.
Online attention
- 155 tweeters
- 2 blogs
- 1 Facebook pages
- 11 news outlets
- 5 Wikipedia page
- 361 Mendeley
This article is in the 98th percentile (ranked 7,343rd) of the 467,095 tracked articles of a similar age in all journals and the 89th percentile (ranked 6th) of the 58 tracked articles of a similar age in Nature Reviews Drug Discovery
View more on Altmetric
Altmetric calculates a score based on the online attention an article receives. Each coloured thread in the circle represents a different type of online attention. The number in the centre is the Altmetric score. Social media and mainstream news media are the main sources that calculate the score. Reference managers such as Mendeley are also tracked but do not contribute to the score. Older articles often score higher because they have had more time to get noticed. To account for this, Altmetric has included the context data for other articles of a similar age.
Mentions in news and blogs
-
新型靶向药物PI3K抑制剂助力滤泡性淋巴瘤治疗新时代
CN-Healthcare -
【前沿追踪】PI3K接连“塌房” 实体瘤?联合用药?药企仍有可为
CN-Healthcare -
Approaches to the molecular pharmacology of PI3Kδ
Cancer Community Nature -
Inavolisib
New Drug Approvals
This list highlights individual mainstream news articles and blogs that cite the article. Not all news and blogs link to articles in a way that Altmetric can pick up, so they are not representative of all media. Altmetric are responsible for the curation of this list and provide updates hourly.